ABSTRACT
OBJECTIVE To provide reference for strengthening the quality of pharmaceutical care in retail chain pharmacies and the professional capabilities of licensed pharmacists， and to meet the public’s pharmaceutical care needs. METHODS A combination of questionnaire survey and informant interview was used to investigate the general information of licensed pharmacists in retail chain pharmacies in Guangdong province， the implementation of pharmaceutical care， the competence and knowledge status of the surveyed licensed pharmacists， and the factors affecting the development of pharmaceutical care. RESULTS & CONCLUSIONS A total of 444 questionnaires were sent out and 326 effective questionnaires were collected， with an effective recovery rate of 73.42%. Among 326 surveyed licensed pharmacists， a college degree or higher accounted for 40.18%， and the pharmacy major or related accounted for 79.75%. A total of 185 （56.75%） of the surveyed licensed pharmacists indicated that the retail chain pharmacies where they worked had established specified areas of pharmaceutical care； 320 （98.16%）， 137 （42.02%） and 181 （55.52%） of the surveyed licensed pharmacists indicated that the retail chain pharmacies where they worked could provide services such as rational medication guidance for patients， decocting traditional Chinese medicines and establishing health records， etc. The self-assessment scores of the surveyed licensed pharmacists were significantly higher than 3 （median） for competence and knowledge level， but the self-assessment scores for medication therapy management competence and pharmaceutical care practice were relatively low. The surveyed licensed pharmacists believed that the main factors affecting the development of pharmaceutical care in retail chain pharmacies included patients’ lack of trust or cooperation （196， 60.12%）， sales performance requirements （170， 52.15%）， and heavy daily workload （165， 50.61%）. It is recommended that relevant authorities expedite the legislative process of the Pharmacist Law， optimize the continuing education system for licensed pharmacists， and implement a star-rating evaluation system for pharmaceutical care capabilities in pharmacies， so as to encourage retail chain pharmacies and licensed pharmacists to pursue a more specialized development path. At the same time， pharmaceutical retail chain enterprises should shift their business mindset， increase investment in pharmaceutical care， enhance the professional atmosphere in the pharmacies， optimize the compensation structure for licensed pharmacists， and elevate the pharmaceutical care capabilities of both the pharmacies and licensed pharmacists to fulfill the pharmaceutical care needs of the public.
ABSTRACT
OBJECTIVE To provide reference for improving the techn ological innovation efficiency of biopharmaceutical enterprises in China. METHODS In this research ，the technological innovation process of the biopharmaceutical enterprises was divided into two stages ：the technological development and the achievement transformation. Two-stage data envelopment analysis （DEA） model was established under the premise of considering the two-stage correlation ，and the two-stage technological innovation efficiency of 23 listed biopharmaceutical enterprises in China was evaluated from 2016 to 2020 on the basis of hysteresis effect. RESULTS & CONCLUSIONS The two-stage technological innovation efficiency of listed biopharmaceutical enterprises in China was at a relatively low level ，and the average overall efficiency of the technological development stage and the achievement transformation stage were only 0.377 and 0.347. At present ，the low efficiency of technology is the main factor restricting the improvement of the two-stage technological innovation efficiency of listed biopharmaceutical enterprises in China. In the technology development stage ，redundant investment in R&D funds and insufficient patent output are the main reasons for the invalid DEA of listed biopharmaceutical enterprises ，while in the achievement transformation stage ，the redundant input of invention patents is the main reason for the invalid DEA of listed biopharmaceutical enterprises. From a regional perspective ，in the technology development stage ，the average overall efficiency and technical efficiency of listed biopharmaceutical enterprises in the eastern region are 0.378 and 0.603，which are higher than the central and western regions. In the stage of achievement transformation，the average values of comprehensive efficiency and technical efficiency of listed biopharmaceutical enterprises in the central and western regions are 0.361 and 0.548，which are higher than those in the eastern region. It is suggested that biopharmaceutical enterprises should enhance their ability to transform technological achievements ，optimize the allocation of scientific and technological resources ，attach importance to （No.2021GXJK332） regional cooperation and exchanges ， promote the overall innovation efficiency of biopharmaceutical industry in China.
ABSTRACT
OBJECTIVE：To pro vide reference for improving i nnovation and development capability of pharmaceutical enterprises in China. METHODS ：Based literature review ，10 measurement indexes （growth rate of net profit ，the growth rate of total assets ，the growth rate of revenue ，the net interest rate of sales ，the gross profit rate of sales ，the rate of return on net assets ， the current ratio ，the asset liability ratio ，the proportion of R&D personnel ，and R&D intensity ）were selected from aspect of growth ability ，profitability，solvency and innovation capability to establish evaluation system. Pharmaceutical enterprises with A-share listing time of no less than 5 years and R&D investment of no less than 100 million yuan in 2018 were selected as the research objects ，the data of above-mentioned indexes of included enterprises were collected during 2015-2019 by means of their public corporate annual reports and stock trading software Tonghuashun ；factor analysis method was used to extract the principal components to establish a model ；principal component factors were determined according to factor characteristic root and variance contribution rate ，ranked and analyzed the average comprehensive score of included enterprises during 2015-2019. RESULTS & CONCLUSIONS：Four principal components including market development capability ，enterprise growth ability ，operation development capability and product innovation capability were determined ，and the cumulative variance contribution rate was 72.385％. A total of 44 pharmaceutical enterprises were included. Among them ，40.91％，43.18％，38.64％，72.73％ and 52.27％ showed an upward trend in the market development capability ，onterprises growth capability ，operational development capability ， product innovation capacity and total innovation and development capability. The highest score of innovation and development capability of pharmaceutical enterprises was 0.612，and the lowest score was － 1.132. There were 8 enterprises whose comprehensive score was 0.3-＜0.7，accounting for 18.18％； pharmaceutical enterprises in this range had good innovation and development capability. There were 21 enterprises whose qq.com comprehensive score was －0.1-＜0.3，accounting for 47.73％； pharmaceutical enterprises in this range had fair good innovation and development capability. There were 11 enter- prises whose comprehensive scor e was －0.5-＜－0.1，accounting for 25.00％；pharmaceutical enterprises in this range had poor innovation and development capability. There were 4 enterprises whose comprehensive score was ＜－0.5，accounting for 9.09％； pharmaceutical enterprises in this range had very poor innovation and development capability. The innovation and development capabilities of pharmaceutical enterprises in China are polarized ，the development of enterprises in China has entered a period of fluctuation with opportunities and challenges coexisting. Pharmaceutical enterprises with a certain number of medical insurance varieties or exclusive core varieties have strong competitiveness in their subdivided pharmaceutical field. Biopharmaceuticals have entered the active period. Pharmaceutical enterprises have shifted from generic drugs to innovative drugs. It is suggested that Chinese pharmaceutical enterprises should implement intelligent management ， develop R&D strategy scientifically ， attach importance to developing international market so as to improve their innovation and development ability.